Lynne Kelley has joined X4 Pharmaceuticals (NASDAQ: XFOR) as chief medical officer, the same post she held at her former company, Histogenics (NASDAQ: HSGX). Kelley’s experience also includes positions at Senseonics (NASDAQ: SENS), Becton Dickinson (NYSE: BDX), Kimberly-Clark (NYSE: KMB), and Boston Scientific (NYSE: BSX). Cambridge, MA-based X4’s lead drug, Mavorixafor, is being prepared for Phase 3 studies in WHIM syndrome, a rare, inherited immunodeficiency.